Can a new daily pill slow lung scarring in IPF?

NCT ID NCT07728721

Not yet recruiting Disease control Sponsor: Haisco Pharmaceutical Group Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether an experimental drug called HSK50042 can improve lung function in adults with idiopathic pulmonary fibrosis (IPF), a chronic condition that causes lung scarring and breathing difficulties. Participants take HSK50042 or a placebo once daily for 26 weeks. The study measures changes in forced vital capacity (a key lung function test) at 12 and 26 weeks to see if the drug slows disease progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental drug called HSK50042 taken orally once daily
What this could lead to: If successful, this could point toward a new treatment option for idiopathic pulmonary fibrosis, potentially slowing lung function decline.
What could go wrong: This is an early-phase trial with a small number of participants, so results may not confirm effectiveness. The drug may cause side effects or fail to improve lung function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS (IPF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IDIOPATHIC PULMONARY FIBROSIS (IPF)

More trials for these conditions

Other studies related to the condition(s) this trial covers.